The Long History of mRNA Vaccines | Johns Hopkins
Messenger RNA, or mRNA, was discovered in the early 1960s; research into how mRNA could be delivered into cells was developed in the 1970s.
The research slowed over the years, and the Pandemic brought it back to life in a big way. And swiftly... being many companies and countries found the monies to make it happen. https://publichealth.jhu.edu/2021/the-long-history-of-mrna-vaccines
Cancer Vaccines - a review
Cancer vaccines have the potential to make conventional immunotherapy more effective, and a number of cancer vaccines are entering clinical trials across the globe. These fall into one of two categories: personalised cancer immunotherapies, which rely on extracting a patient’s own genetic material from their tumours; and therapeutic cancer immunotherapies, like mRNA-4359, which are ‘ready made’ and tailored to a particular type of cancer.
The testing of the mRNA vaccine for Melanoma cancer has been quite successful although still in the very early stages.. It has been approved for trials in high risk individuals in the UK and hundreds are now in the phase 3 trial. https://www.theguardian.com/society/2024/apr/26/cancer-mrna-vaccine-melanoma-trial
Oncologist Professor Price discusses the world's first personalised mRNA vaccine for melanoma
Pancreatic cancer vaccines are in stage 2 of trials in the US.
The University of Cincinnati Cancer Center's groundbreaking initiation of a Phase 2 clinical trial for a pancreatic cancer vaccine heralds a potentially transformative advance in this grim landscape. This trial, leveraging the pioneering mRNA technology that paved the way for COVID-19 vaccines, signifies a beacon of hope for over 66,000 Americans anticipated to confront this disease in 2024. It underscores a promising horizon in the battle against pancreatic cancer, offering a glimpse into the future of personalized, immune-based therapies.